StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note released on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
TTNP stock opened at $3.64 on Friday. The company’s 50 day moving average price is $3.76 and its 200 day moving average price is $3.82. The firm has a market capitalization of $3.32 million, a price-to-earnings ratio of -0.70 and a beta of 1.27. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- Short Selling – The Pros and Cons
- 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
- Where Do I Find 52-Week Highs and Lows?
- These 3 Stocks Have Huge Last 12 Months Shareholder Yields
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
